Modality-specific outcomes of SRS and FSRT for benign meningiomas are unclear. Significant differences in tumor regression rates between SRS and FSRT were found. No difference in survival, local control and complication rate between SRS and FSRT. SRS and FSRT are likely comparable treatments for benign intracranial meningioma.